Tenalisib R Enantiomer is used in research and development of anti-cancer drugs, particularly for hematologic malignancies such as lymphoma and leukemia. It inhibits the PI3K delta enzyme, which is involved in the growth and survival of cancer cells. Clinical studies demonstrate its potential to reduce tumor size and slow disease progression. Additionally, its efficacy and safety in combination with other drugs are being investigated to improve treatment outcomes.